A Study of Teriparatide in Japanese Osteoporosis Patients

Inclusion Criteria: * Ambulatory Japanese males or postmenopausal females with osteoporosis, as determined by the Japanese Society for Bone and Mineral Research (JSBMR) diagnostic criteria Exclusion Criteria: * Prior treatment with parathyroid hormone (PTH) or any PTH analog * History of metabolic bone disorders other than primary osteoporosis * Fractures caused by diseases other than osteoporosis * Abnormal thyroid function * Hyperparathyroidism or hypoparathyroidism * Severe or chronically disabling conditions other than osteoporosis * Currently has or has a history of spruce, inflammatory bowel disease, or malabsorption syndrome * Currently has, or a has a history of, nephrolithiasis or urolithiasis in the 2 years prior to screening * Clinically significant abnormal laboratory values or electrocardiogram * Treatment with oral bisphosphonates at any time in the 3 months prior to enrollment, treatment with any bisphosphonate for more than 60 days in the 6 months prior to enrollment, or with intravenous bisphosphonates at any time in the 24 months prior to enrollment; or in case of oral bisphosphonates administered once a week, the equivalent as the above * Treatment with injectable calcitonin in the 3 months prior to enrollment * Treatment with raloxifene hydrochloride for more than 3 months in the 6 months prior to enrollment * Treatment with systemic corticosteroids, except for orally inhaled or nasally inhaled corticosteroids, in doses \<= 800 micrograms per day (µg/day) beclomethasone dipropionate or equivalent in the 3 months prior to screening, or for more than 30 days in the 12 months prior to enrollment * Treatment with anticonvulsants, except for benzodiazepines, in the 6 months prior to enrollment * Prior treatment with strontiumranate or denosumab (anti-RANKL antibody) * Prior external beam radiation therapy involving the skeleton * Current or a history of malignant neoplasm in the 5 years prior to screening, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that had been definitively treated